Literature DB >> 3011860

Anti-F(ab')2 antibodies in thrombocytopenic patients at risk for acquired immunodeficiency syndrome.

J R Yu, E T Lennette, S Karpatkin.   

Abstract

22 homosexual or narcotic addict patients at risk for acquired immunodeficiency syndrome (AIDS) or with AIDS, were studied for the presence of antiimmunoglobulin antibodies and circulating immune complexes (20 were thrombocytopenic, 6 had AIDS). Circulating immune complex levels were 10-fold higher than levels in normal subjects. IgG anti-F(ab')2 antibodies were noted in homosexual as well as narcotic addict patients. Of 16 homosexual patients, 7 had IgG anti-F(ab')2 antibody of moderate to marked titer with broad reactivity against autologous, homologous, and control F(ab')2 fragments. Three others demonstrated limited reactivity against one or two F(ab')2 fragments. The remaining six patients were negative. Six of six narcotic addict patients had IgG anti-F(ab')2 antibody, five with limited reactivity, one with broad reactivity. In contrast, neither elevated circulating immune complexes nor anti-F(ab')2 antibodies were detectable in six autoimmune thrombocytopenic patients. Anti-F(ab')2 antibody could be affinity purified from serum or circulating immune complexes. Anti-F(ab')2 reactivity correlated with circulating immune complex levels, r = 0.83, P less than 0.01.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011860      PMCID: PMC370530          DOI: 10.1172/JCI112498

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

Review 1.  Autoimmune thrombocytopenic purpura.

Authors:  S Karpatkin
Journal:  Semin Hematol       Date:  1985-10       Impact factor: 3.851

2.  Naturally occurring circulating immune complexes: normal human serum contains idiotype-anti-idiotype complexes dissociable by certain IgG antiglobulins.

Authors:  A C Morgan; R D Rossen; J J Twomey
Journal:  J Immunol       Date:  1979-05       Impact factor: 5.422

3.  Specificity of autoantibodies in autoimmune thrombocytopenia.

Authors:  E F van Leeuwen; J T van der Ven; C P Engelfriet; A E von dem Borne
Journal:  Blood       Date:  1982-01       Impact factor: 22.113

4.  Thrombocytopenic purpura in narcotics addicts.

Authors:  S Savona; M A Nardi; E T Lennette; S Karpatkin
Journal:  Ann Intern Med       Date:  1985-06       Impact factor: 25.391

5.  The induction of a rheumatoid factor-like substance in rabbits.

Authors:  J L ABRUZZO; C L CHRISTIAN
Journal:  J Exp Med       Date:  1961-11-01       Impact factor: 14.307

6.  Naturally occurring human antibodies to the F(ab')2 portion of IgG.

Authors:  H Nasu; D S Chia; D W Knutson; E V Barnett
Journal:  Clin Exp Immunol       Date:  1980-11       Impact factor: 4.330

7.  Anti-Fab' antibodies in rheumatoid arthritis. Measurement of the relative quantities incorporated in soluble immune complexes in sera and supernatants from cultured peripheral blood lymphocytes.

Authors:  H H Birdsall; M D Lidsky; R D Rossen
Journal:  Arthritis Rheum       Date:  1983-12

8.  Autoimmune thrombocytopenic purpura in homosexual men.

Authors:  L Morris; A Distenfeld; E Amorosi; S Karpatkin
Journal:  Ann Intern Med       Date:  1982-06       Impact factor: 25.391

9.  Binding of immunoglobulin G aggregates and immune complexes in human sera to Staphylococci containing protein A.

Authors:  J S McDougal; P B Redecha; R D Inman; C L Christian
Journal:  J Clin Invest       Date:  1979-04       Impact factor: 14.808

10.  Anti-Fab antibodies in humans. Predominance of minor immunoglobulin G subclasses in rheumatoid arthritis.

Authors:  J E Persselin; R H Stevens
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

View more
  9 in total

1.  GPIIIa-(49-66) is a major pathophysiologically relevant antigenic determinant for anti-platelet GPIIIa of HIV-1-related immunologic thrombocytopenia.

Authors:  M A Nardi; L X Liu; S Karpatkin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

2.  Sequestration of anti-platelet GPIIIa antibody in rheumatoid factor immune complexes of human immunodeficiency virus 1 thrombocytopenic patients.

Authors:  S Karpatkin; M A Nardi; K B Hymes
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

3.  Autoimmune anti-HIV-1gp120 antibody with antiidiotype-like activity in sera and immune complexes of HIV-1-related immunologic thrombocytopenia.

Authors:  S Karpatkin; M Nardi
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

4.  Pathophysiology of HIV related thrombocytopenia: an analysis of 41 patients.

Authors:  A Domínguez; G Gamallo; R Garcia; A Lopez-Pastor; J M Peña; J J Vazquez
Journal:  J Clin Pathol       Date:  1994-11       Impact factor: 3.411

5.  Anti-human immunodeficiency virus type 1 antibody complexes on platelets of seropositive thrombocytopenic homosexuals and narcotic addicts.

Authors:  S Karpatkin; M Nardi; E T Lennette; B Byrne; B Poiesz
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

Review 6.  Markers predicting progression of human immunodeficiency virus-related disease.

Authors:  C M Tsoukas; N F Bernard
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

Review 7.  DNA inoculation as a novel vaccination method against human retroviruses with rheumatic disease associations.

Authors:  K E Ugen; B Wang; V Ayyavoo; M Agadjanyan; J Boyer; F Li; S Kudchodkar; J Lin; M Merva; L Fernandes
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

8.  Internal-image anti-idiotype HIV-1gp120 antibody in human immunodeficiency virus 1 (HIV-1)-seropositive individuals with thrombocytopenia.

Authors:  S Karpatkin; M A Nardi; Y H Kouri
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

9.  Antiidiotype antibody against platelet anti-GPIIIa contributes to the regulation of thrombocytopenia in HIV-1-ITP patients.

Authors:  M Nardi; S Karpatkin
Journal:  J Exp Med       Date:  2000-06-19       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.